Fig. 3 | Nature Communications

Fig. 3

From: Precision therapeutic targeting of human cancer cell motility

Fig. 3

KBU2046 inhibits bone destruction. a Treatment schema. Athymic mice were given intracardiac (IC) injections of PC3-luc cells on day 0 under ultrasound guidance, and underwent weekly IVIS imaging starting 7 days post injection. Cohorts of N = 20 control, N = 20 pre (treatment from 3 days prior to IC injection through end of the experiment), N = 10 Pre7Stop (treatment from 3 days prior to IC injection through 7 days post IC injection), and N = 10 post-treatment (treatment from 3 days post IC injection through end of the experiment) mice were dosed with 80 mg/kg KBU2046 daily by oral gavage and mock-treated with vehicle all other times. Whole-body (b) and mandible (c) flux are depicted, as determined from weekly IVIS imaging. d At week 4 post injection (i.e., at the end of the experiment), CT scans were performed on control, pre-, and post-treatment cohorts, and mandibular destruction quantified. e Representative images of pre and control mice are depicted. Arrows denote areas of bone destruction in controls, and corresponding areas in the pre mouse. Student’s t-test (b, c) and Fisher’s exact test (d) P values between the denoted cohorts are shown

Back to article page